Demographic Factors Associated with Utilization of Antenatal Care Services Among Pregnant Women in Song Local Government Area of Adamawa State

Yohanna Wamanyi^{1*}, E.S. Samuel² & EkeminiE. Samuel³

^{1,2} Department of Human Kinetics and Health Education, University of Nigeria Nsukka ³University of Port Harcourt Teaching Hospital, Port Harcourt * Corresponding Author:

Abstract

The study was designed to investigate the demographic factors associated with the utilization of antenatal care services among pregnant women in Song local government area, Adamawa State. In order to accomplish this purpose, three specific objectives and corresponding research questions were formulated. Three null hypotheses were postulated for the study. Descriptive survey design was employed for this study. Four hundred (400) sample size was determined using Yaro Yamane's formula for determining sample size of any definite population. The instrument for data collection was questionnaire. Frequencies and percentages were used to answer the research questions, while the hypotheses were tested at .05 level of significance at appropriate degree of freedom using chi-square. A total of 300 (73.8%) pregnant women utilized the components of ANC services. The highest ANC services utilized was health education (96.7%) followed by screening (90.5%), routine drugs (80.8%) and physical examination (65.0%) while the lowest ANC services utilization was immunization (35.7%). There was significant difference in the utilization of ANC services among pregnant women based on age and location; and no significant difference based on parity. The researcher recommended among other things that health education and campaign on adequate utilization of antenatal care services (especially physical examination & immunization) should be conducted by health educators and other health care professionals regularly at health centres, schools, churches, social media, among others.

Keywords: Demographic factors, Utilization, Antenatal care services, Pregnant women.

Introduction

Antenatal care (ANC) is one of the components of maternal health and is a key strategy for reducing maternal and neonatal morbidity and mortality rate worldwide. ANC services and its utilization are associated with improved maternal and neonatal health outcomes. World Health Organization-WHO, United Nations Children Fund-UNICEF, World Bank Group and United Nations Population Division, (2016) reported that approximately 580,000 maternal deaths occurred in 2015 worldwide. The lifetime risk of maternal death in sub-Saharan Africa is one (1) in 22 pregnant mothers compared to one (1) in 210 in Northern Africa, one (1) in 62 for Oceania, one (1) in 120 for Asia, and one (1) in 290 for Latin America and the Caribbean (WHO, 2010). WHO, (2012) stated that in 2010, two countries reported a one third of global maternal deaths: India at 19 per cent (56,000) and Nigeria at 14 per cent (40,000). According to Federal Ministry of Health (2012), some of the dangers of pregnancy and childbirth can be prevented if the pregnant women utilize ANC services regularly. The utilization of ANC services is an important strategy in Nigeria, being the leading contributor to maternal mortality in sub-Saharan Africa.

Antenatal care is a sure way of achieving healthy mother and child. In Nigeria, it was estimated that approximately 59,000 of maternal deaths take place annually as a result of pregnancy, delivery and post-delivery complications, despite the availability of ANC services (World Health Organization-WHO, United Nations Children Fund-UNICEF & United Nations Population Fund-UNFPA, 2007). With an estimated 59,000 maternal deaths, Nigeria which has approximately two per cent of the world's population contributes more than 10 per cent of the world's maternal deaths which can be attributed partly to non-utilization of ANC services (Dairo & Owoyokun, 2010). According to WHO, UNICEF, World Bank Group and United Nations Population Division, maternal mortality ratio

in Nigeria was last measured at 814 in 2015. Utilization of ANC services is one of the most important indicator for controlling maternal morbidity and mortality. ANC has been defined by various authors.

Utilization is to make use of something for its benefit. Utilization is the use of something especially for practical purposes (Onah, Ikeakor & Iloabuchi, 2006). Fosu, (2011) divided utilization into two; low utilization and effective utilization. Low utilization is when less than fifty per cent persons use a given service, whereas effective utilization is when more than fifty per cent of persons use a particular service. WHO, (2005) explained ANC services utilization as using enough visits (at least three) with early timing (first visit during first trimester) and sufficient services (at least six core services according to the experts recommendations). Utilization of ANC services has been identified in a number of studies as an important factor in determining maternal and infant mortality. Villar, (2012) asserted that the trend of maternal mortality in developing countries has been increasing and various international organizations have reported that an important factor related to maternal and infant mortality has been linked to lack of utilization of antenatal care services. According to Federal Ministry of Health (2005), in order to decrease maternal and infant mortality rates, utilization of ANC services has to be instituted or reinforced which can only be achieved through identifying factors causing poor utilization of antenatal care services. Utilization of ANC services refers to attainment of first, second, third and fourth visits to designated clinics by pregnant women (from first trimester till delivery) and the appropriate use of services provided. Utilization of ANC services means the proper use of services provided to pregnant women during pregnancy. Utilization of ANC services among pregnant women is one of the important factors in reducing maternal morbidity and mortality.

Utilization of ANC services helps to reduce maternal morbidity and mortality. Reports showed that a high utilization rate of the ANC service results in lowering the risk of maternal mortality (WHO, 2009). Magadi, Agwanda, and Obare.(2007) posited that the failure to utilize ANC services during pregnancy can lead to undesirable pregnancy outcomes such as maternal morbidity, low birth weight for the baby or even maternal and prenatal mortality. Jibo, (2005) found out two main reasons for non-utilization of ANC services; they are socio-demographic factors and access to experience traditional birth.

Demographic factors are important variables that comprise of demographic characteristics of the subject which may affect health outcomes. Toan, (2012) stated that, demographic factors are variables which include gender, age and total number of person living. Ikeoluwapo, Damilola, Osakinle, (2013) stated that, a number of demographic factors are associated with increased risk for preterm birth. The author further mentioned; young maternal age, maternal age over 35, and pregnancy for single mother and those cohabiting under marriage as associating with increased risk. Emelumadu, Ukegbu, Ezeama, Kanu, Ifeadike and Onyeonoro, (2015) listed demographic characteristics to include age, sex, place of residence, religion and marital status. For the purpose of this study, the following variables will be investigated; age, parity and location. The above factors have the potentials of restricting or enhancing the utilization of ANC among pregnant women in Song Local Government Area, Adamawa State.

The study was conducted in health care facilities that provide ANC services in Song Local Government Area of Adamawa State. The study was delimited to pregnant women in Song LGA, Adamawa state. The study focused on utilization of ANC services among pregnant women, and the relationship between demographic variables associated with utilization of ANC such as age, location and parity.

Method

In order to accomplish the purpose of this research, a cross-sectioned descriptive survey design was employed. The study was conducted in health care facilities that provided ANC services in Song Local Government Area of Adamawa State. The population for this study consisted of all pregnant women attending antenatal care clinic across Song Local Government Area, Adamawa State. The population of pregnant women was 12, 823 as at May, 2016 (Adamawa State Primary Health Care Development Agency-ADPHCDA, 2016). The sample for this study consisted of 400 pregnant women. This was calculated using Yaro Yamane's formula for determining the sample size of any definite population (Gemson & Kyamru, 2013). The instrument for data collection was researcher-designed questionnaire tagged 'Socio-demographic Factors Associated with Utilization of Antenatal Care Services Questionnaire (SODEFAS-Q). The data derived from the SODEFAS-Q were based on

2-point scale Yes or No. The respondents were requested to place a tick $[\sqrt{}]$ as it applied to them in sections A and B.

The face validity of the instrument was established by giving the drafted copies of the questionnaire accompanied with the purpose of the study and its specific objectives, the research questions and hypotheses to five experts, who critically examined them and ascertain whether the items covered the objectives of the study. The experts were from the Department of Human Kinetic and Health Education, University of Nigeria, Nsukka. The reliability of the instrument was computed using Crombach gave a valued .68, and the instrument was adjudged reliable. The data were analyzed using frequencies and percentages to answer the research questions. The null hypotheses were tested using chi-square at .05 level of significance at appropriate degree of freedom.

Results

| Proportion of Pregnant women Utilizing Components of ANC Services (n=40) | izing Components of ANC Services (n=407) | gnant Women Utilizing | Proportion |
|--|--|-----------------------|------------|
|--|--|-----------------------|------------|

| S/n | Items | Y | es | No | | | | |
|-----|----------------------------------|-----|------|-----|------|--|--|--|
| | | F | % | F | % | | | |
| | Health Education | | | | | | | |
| 1 | Exclusive breast feeding | 394 | 96.8 | 13 | 3.2 | | | |
| 2 | Nutrition | 398 | 97.8 | 9 | 2.2 | | | |
| 3 | Family planning | 398 | 97.8 | 9 | 2.2 | | | |
| 4 | Personal hygiene | 398 | 97.8 | 9 | 2.2 | | | |
| 5 | Exercise | 379 | 93.1 | 28 | 6.9 | | | |
| | Cluster % | 393 | 96.7 | 14 | 3.3 | | | |
| | Routine Drugs | | | | | | | |
| 6 | Ferrous sulphate | 402 | 98.8 | 5 | 1.2 | | | |
| 7 | Folic acid | 387 | 95.1 | 20 | 4.9 | | | |
| 8 | Multivitamin tablets | 391 | 96.1 | 16 | 3.9 | | | |
| 9 | Vitamin B complex | 131 | 32.2 | 276 | 67.8 | | | |
| 10 | Vitamin C tablets | 333 | 81.8 | 74 | 18.2 | | | |
| | Cluster % | 329 | 80.8 | 78 | 19.2 | | | |
| | Physical Examination | | | | | | | |
| 11 | Abdominal palpation | 397 | 97.5 | 10 | 2.5 | | | |
| 12 | Breast examination | 260 | 63.9 | 147 | 36.1 | | | |
| 13 | Examination of skin | 204 | 50.1 | 203 | 49.9 | | | |
| 14 | Examination of private part | 198 | 48.6 | 209 | 51.4 | | | |
| | Cluster % | 265 | 65.0 | 142 | 35.0 | | | |
| | Screening | | | | | | | |
| 15 | HIV test | 388 | 95.3 | 19 | 4.7 | | | |
| 16 | Urine test for protein and sugar | 376 | 92.4 | 31 | 7.6 | | | |
| 17 | Blood test for anaemia | 364 | 89.4 | 43 | 10.6 | | | |
| 18 | Blood test for malaria parasite | 317 | 77.9 | 90 | 22.1 | | | |
| 19 | BP measurement | 397 | 97.5 | 10 | 2.5 | | | |
| | Cluster % | 368 | 90.5 | 39 | 9.5 | | | |
| | Immunization | | | | | | | |
| 20 | TT1 dose | 380 | 93.4 | 27 | 6.6 | | | |
| 21 | TT2 dose | 286 | 70.3 | 121 | 29.7 | | | |
| 22 | TT3 dose | 35 | 8.6 | 372 | 91.4 | | | |
| 23 | TT4 dose | 3 | 0.7 | 404 | 99.3 | | | |
| 24 | TT5 dose | 23 | 5.7 | 384 | 94.3 | | | |
| | Cluster % | 145 | 35.7 | 262 | 64.3 | | | |
| | Overall % | 300 | 73.8 | 107 | 26.2 | | | |

Table 1

Data in Table 1 show that overall 73.8% of pregnant women utilized ANC services. This shows high proportion of utilization. The table further reveals the proportion of respondents that utilized specific ANC services as follows: health education (96.7%), screening (90.5%), routine drugs (80.8%), physical examination (65.0%) and immunization (35.7%). Besides immunization with low proportion of utilization (35.7%), other components of ANC services were highly utilized.

| Table 2 | |
|--|------------------|
| Proportion of Utilization of ANC Services Among Pregnant Women Based | l on Age (n=407) |

| | 37.5) 100.0) 37.5) 00.0) '5.0) 0 |
|---|--|
| Yes (%)No (%)Yes (%)No (%)Yes (%)No (%)Yes (%)No (%)Yes (%)No (%)Yes (%)No (%)Yes (%)No (%)Yes (%)No | 37.5) 100.0) 37.5) 00.0) 5.0) 0 |
| Health Education Exclusive breast feeding 1(x0) 1(x0) <th>37.5) 100.0) 37.5) .00.0) '5.0) .0</th> | 37.5) 100.0) 37.5) .00.0) '5.0) .0 |
| Exclusive breast feeding Exclusive breast feeding Za3. S8(96.7) 3(1.9) IS8(98.1) 2(1.8) 109(98.2) S(7.5) 62(92.5) 1(12.5) 7(87) Pamily planning Za3. S8(96.7) 3(1.9) IS8(98.1) 2(1.8) 109(98.2) Z(3.0) 65(97.0) 1(12.5) 66(98.5) 0(0.0) 8(10 Pamily planning Za3.0 S7(95.0) 2(1.2) IS9(98.3) 2(1.8) 109(98.2) Z(3.0) 65(97.0) 1(12.5) 66(98.5) 0(0.0) 8(10 Cluster % Routine Drugs Parcons sulphate X7 96.3 2(1.2) IS9(98.8) 2(1.8) 109(91.0) 1(15.0) 66(98.5) 0(0.0) 6(75 Cluster % Routine Drugs Parcons sulphate 0(0.00 60(100.0) 6(3.7) IS5(96.3) 2(1.8) 109(98.2) 1(1.5) 66(98.5) 0(0.0) 6(75 Multivitamin tables Qa3.0 S8(96.7) G(3.7) IS5(96.3) 2(1.8) 109(98.2) 1(1.5) 66(98.5) 0(0.0) 6(22.5) 6(6.5) 2(2.5) | 87.5) 100.0) 87.5) 00.0) '5.0) .0 |
| 1 feeding 243.3 58/06.7 3(1.9) 158/08.1) 2(1.8) 109/08.2) 5(7.5) 6(292.5) 0(0.0) 8(10 2 Murinion 2(3.3) 58/06.7) 3(1.9) 158/08.1) 2(1.8) 109(98.2) 5(7.5) 6(292.5) 0(0.0) 8(10 3 Personal hygiene 1 59/08.3 3(2.7) 108(97.3) 1(1.5) 66(98.5) 0(0.0) 6(7.5) 6(7.5) 4 Personal hygiene 3(5.0) 57(95.0) 2(1.2) 159(98.8) 3(2.7) 108(97.3) 1(1.5) 66(98.5) 0(0.0) 6(7.5) 5 Exercise 3(7.9) 96.3 2.5 97.5 3.6 09(98.2) 1(1.5) 66(98.5) 0(0.0) 6(7.5) 6 Exercise 0(0.00 60(100.0) 2(1.2) 159(96.3) 2(1.8) 109(98.2) 1(1.5) 6(98.5) 0(0.0) 2(2.5) 6(7.5) 7 Foits acid 0(0.00 0(0100.0) 6(3.7) 155(96.3) 2(1.8) | 37.5) 100.0) 37.5) .00.0) '5.0) .0 |
| 213 58(96.7) 3(1.9) 158(98.1) 2(1.8) 109(98.2) 5(7.5) 62(92.5) 1(1.2.5) 7(87 3 Family planning 2(3.3) 58(96.7) 3(1.9) 158(98.1) 3(2.7) 108(97.3) 1(1.5) 66(98.5) 0(0.0) 8(10 4 Personal hygiene 3(5.0) 57(95.0) 2(1.2) 159(98.8) 3(2.7) 108(97.3) 1(1.5) 66(98.5) 0(0.0) 8(01 5 Exercise 3(5.0) 57(95.0) 2(1.2) 159(98.8) 2(1.8) 109(98.2) 1(1.5) 66(98.5) 0(0.0) 8(01 6 C 0 0 9(1.0) 4(6.0) 63(94.0) 2(25.0) 6(75 7 Folic acid 0(0.0) 60(100.0) 2(1.2) 159(98.8) 2(1.8) 109(98.2) 1(1.5) 66(98.5) 0(0.0) 8(10 7 Folic acid 0(0.0) 60(100.0) 2(1.2) 159(98.8) 2(1.8) 109(98.2) 1(1.5) 66(98.5) 0(0.0) 8 | 37.5) 100.0) 37.5) (00.0) '5.0) .0 |
| 2 Nutrition 2(3.3) 58(96.7) 3(1.9) 158(98.1) 3(2.7) 108(97.3) 1(1.5) 66(98.5) 0(.0) 8(10) 3 Family planning 1(1.7) 59(98.3) 3(1.9) 158(98.1) 2(1.8) 109(98.2) 2(3.0) 65(97.0) 1(1.2.5) 7(87) 4 Personal hygiene 3(5.0) 57(95.0) 9(5.6) 152(94.4) 109(98.2) 1(1.5) 66(98.5) 0(0.0) 8(10) Cluster % 3.7 96.3 2.5 97.5 3.6 96.4 3.9 9(-1 10.0 9(0.0) 8(10) 6 0(0.0) 60(10.0) 2(1.2) 159(98.8) 2(1.8) 109(98.2) 1(1.5) 66(98.5) 0(0.0) 8(10) 7 Folic acid 0(00.0) 60(10.0) 2(1.2) 159(98.8) 2(1.8) 109(98.2) 1(1.5) 66(98.5) 0(0.0) 8(10 8 Multivitamin tablets 2(3.3) 58(96.7) 6(3.7) 155(96.3) 2(1.8) 109(98.2) | 100.0) 37.5) 100.0) '5.0) .0 |
| 3 Family planning 1(1.7) 59(98.3) 3(1.9) 158(98.1) 2(1.8) 109(98.2) 2(3.0) 65(97.0) 1(12.5) 7(87) 4 Personal hygiene 3(5.0) 57(95.0) 2(1.2) 159(98.8) 3(2.7) 108(97.3) 1(1.5) 66(98.5) 0(0.0) 6(75) 5 Exercise 3(5.0) 57(95.0) 9(5.6) 152(94.4) 10(9.0) 101(91.0) 4(6.0) 63(94.0) 2(25.0) 6(75) 6 Chuiter Ya 3.7 96.3 2.5 97.5 3.6 96.4 3.9 96.1 10.0 90.0 6 Chuiter Ya 3.7 96.3 2.5 97.5 3.6 96.4 3.9 96.1 10.0 90.0 7 Folic acid 00(0.0) 60(100.0) 2(1.2) 159(96.3) 2(1.8) 109(98.2) 1(1.5) 66(98.5) 00.0.0 67.50 9 Vitamin B complex 40(66.7) 20(33.3) 18(7.3) 43(26.7) 69(62.2) 42 | 87.5) 100.0) 75.0) .0 |
| 4 Personal hygiene 1000000000000000000000000000000000000 | 100.0) 75.0) .0 |
| 1 Clashin Figure 3(5.0) 57(95.0) 2(1.2) 159(98.8) 3(2.7) 108(97.3) 1(1.5) 66(98.5) 0(0.0) 8(10) 5 Exercise 3(5.0) 57(95.0) 9(5.6) 152(94.4) 10(9.0) 101(91.0) 4(6.0) 63(94.0) 2(25.0) 6(75 Routine Drugs Ferrous sulphate 96.3 2.5 97.5 3.6 96.4 3.9 96.1 10.0 90.0 7 Folic acid 0(0.0) 60(100.0) 2(1.2) 159(98.8) 2(1.8) 109(98.2) 1(1.5) 66(98.5) 0(0.0) 8(10 7 Folic acid 0(0.0) 60(100.0) 2(1.2) 159(98.3) 2(1.8) 109(98.2) 1(1.5) 66(98.5) 0(0.0) 8(10 7 Folic acid 0(06.7) 20(33.3) 118(73.3) 43(26.7) 69(62.2) 42(37.8) 43(64.2) 24(35.8) 6(75.0) 2(25.0) 6(75 9 Vitamin C tablets 14(23.3) 46(76.7) 17(10.6) 144(89.4) 24(21.6) 87(78.4) 17(25.4) 50(74.6) 2(25.0) | 100.0) 75.0) . 0 |
| 5 Exercise 3(5.0) 57(95.0) 9(5.5) 152(94.4) 10(9.0) 101(91.0) 4(6.0) 63(94.0) 2(25.0) 6(75 Cluster % 3.7 96.3 2.5 97.5 3.6 96.4 3.9 96.1 10.0 90.0 6 Cluster % 3.7 96.3 2.5 97.5 3.6 96.4 3.9 96.1 10.0 90.0 6 Cluster % 3.7 96.3 2.5 97.5 3.6 96.4 3.9 96.1 10.0 90.0 6 Cluster % 0(0.0) 60(100.0) 2(1.2) 155(96.3) 5(4.5) 106(95.5) 7(10.4) 60(88.6) 2(25.0) 6(75 9 Vitamin B complex 40(66.7) 20(33.3) 118(73.3) 43(26.7) 69(62.2) 42(37.8) 43(64.2) 24(35.8) 6(75.0) 7(25.4) 50(74.6) 2(25.0) 6(75 9 Vitamin C tablets 14(23.3) 46(67.7) 17(10.6) 144.89.4) 24(21 | 75.0) . 0 |
| Cluster % Routine Drugs Ferrous subplate 3.7 96.3 2.5 97.5 3.6 96.4 3.9 96.1 10.0 90.0 6 <t< th=""><th>.0</th></t<> | .0 |
| Routine Drugs Ferrous sulphate 6 0(0.0) 60(100.0) 2(1.2) 159(98.8) 2(1.8) 109(98.2) 1(1.5) 66(98.5) 0(0.0) 6(0.0) 6(0.7) 7 Folic acid 0(0.0) 60(100.0) 6(3.7) 155(96.3) 5(4.5) 109(98.2) 1(1.5) 66(98.5) 0(0.0) 6(0.7) 9 Vitamin tablets 2(3.3) 58(96.7) 6(3.7) 155(96.3) 2(1.8) 109(98.2) 4(6.0) 63(94.0) 2(2.50) 6(75 9 Vitamin B complex 40(66.7) 20(3.3.3) 118(73.3) 43(26.7) 69(62.2) 42(37.8) 43(64.2) 24(35.8) 6(75.0) 2(2.50) 6(75 14(23.3) 46(76.7) 17(10.6) 144(89.4) 24(21.6) 87(78.4) 17(25.4) 50(74.6) 2(2.50) 6(75.0) 18.7 18.7 81.5 18.7 18.4 81.6 21.5 78.5 30.0 70.0 <th< th=""><th></th></th<> | |
| Ferrous sulphate Ferrous sulphate 6 0(0.0) 60(10.0) 2(1.2) 159(98.8) 2(1.8) 109(98.2) 1(1.5) 66(98.5) 0(0.0) 6(17) 8 Multivitamin tablets 2(3.3) 58(96.7) 6(3.7) 155(96.3) 2(1.8) 109(98.2) 1(1.5) 66(98.5) 0(0.0) 6(75 9 Vitamin B complex 2(3.3) 58(96.7) 6(3.7) 155(96.3) 2(1.8) 109(98.2) 4(6.0) 63(94.0) 2(25.0) 6(75 9 Vitamin C tablets 40(66.7) 20(33.3) 118(73.3) 43(26.7) 69(62.2) 42(37.8) 43(64.2) 24(35.8) 6(75.0) 2(25 10 Vitamin C tablets 14(23.3) 46(76.7) 17(10.6) 144(89.4) 24(21.6) 87(78.4) 17(25.4) 50(74.6) 2(25.0) 6(75 9 Physical Examination 18.7 81.5 81.5 81.5 18.4 81.6 21.5 78.5 30.0 70.0 11 Abdominal </th <th></th> | |
| 6 0(0.0) 60(100.0) 2(1.2) 159(98.8) 2(1.8) 109(98.2) 1(1.5) 66(98.5) 0(0.0) 60(0) 7 Folic acid 0(0.0) 60(100.0) 6(3.7) 155(96.3) 5(4.5) 106(95.5) 7(10.4) 66(98.5) 0(0.0) 6(75 9 Vitamin B complex 40(66.7) 20(33.3) 118(73.3) 43(26.7) 69(62.2) 42(37.8) 43(64.2) 24(35.8) 6(75.0) 2(25.0) 6(75 10 Vitamin C tablets 14(23.3) 46(76.7) 17(10.6) 144(89.4) 24(21.6) 87(78.4) 17(25.4) 50(74.6) 2(25.0) 6(75 Physical Examination 18.7 81.3 18.5 18.4 81.6 21.5 78.5 30.0 70.0 11 Abdominal palpation 1(1.7) 59(98.3) 6(3.7) 2(1.8) 109(98.2) 1(1.5) 66(98.5) 0(0.0) 8(10 12 Breast examination 30(50.0) 30(50.0) 56(34.8) 105(65.2) 35(31 | |
| oli:00 oli:000 oli:000 <th< th=""><th>00.0</th></th<> | 00.0 |
| Formation | 25 (I) |
| 3 Main Hamma Bases 2(3.3) 58(96.7) 6(3.7) 155(96.3) 2(1.8) 109(98.2) 4(6.0) 63(94.0) 2(25.0) 6(75 9 Vitamin B complex 40(66.7) 20(33.3) 118(73.3) 43(26.7) 69(62.2) 42(37.8) 43(64.2) 24(35.8) 6(75.0) 2(25 10 Vitamin C tablets 14(23.3) 46(76.7) 17(10.6) 144(89.4) 24(21.6) 87(78.4) 17(25.4) 50(74.6) 2(25.0) 6(75 Physical Examination 11.7 59(98.3) 6(3.7) 2(1.8) 109(98.2) 1(1.5) 66(98.5) 0(0.0) 8(10 12 Breast examination 1(1.7) 59(98.3) 6(3.7) 2(1.8) 109(98.2) 1(1.5) 66(98.5) 0(0.0) 8(10 13 Examination of skin 40(66.7) 20(33.3) 71(44.1) 90(55.9) 47(42.3) 64(57.7) 39(58.2) 28(41.8) 6(75.0) 2(25 14 Examination of skin 40(66.7) 52.5 31.5 68.5 30.2 69.8 39.2 60.8 40.6 594 | 5.0) |
| 9 Vitamin B complex 40(66.7) 20(33.3) 118(73.3) 43(26.7) 69(62.2) 42(37.8) 43(64.2) 24(35.8) 6(75.0) 2(25.0) 6(75.0) 2(25.0) 6(75.0) 2(25.0) 6(75.0) 2(25.0) 6(75.0) 2(25.0) 6(75.0) 2(25.0) 6(75.0) 2(25.0) 6(75.0) 2(25.0) 6(75.0) 2(25.0) 6(75.0) 2(25.0) 6(75.0) 2(25.0) 6(75.0) 2(25.0) 6(75.0) 2(25.0) 6(75.0) 2(25.0) 6(75.0) 2(25.0) 6(75.0) 2(25.0) 6(75.0) 2(25.0) 6(75.0) 78.5 30.0 70.0 11 Abdominal palpation 1(1.7) 59(98.3) 6(3.7) 2(1.8) 109(98.2) 1(1.5) 66(98.5) 0(0.0) 8(10 12 Breast examination 1(1.7) 59(98.3) 6(3.7) 2(1.8) 109(98.2) 1(1.5) 66(98.5) 0(0.0) 8(10 13 Examination of skin 40(66.7) 20(33.3) 71(44.1) 90(55.9) 47(42.3) 64(57.7) 39(58.2) 28(41.8) 6(75.0) 2(25 14 Examination of | (5.0) |
| $\begin{array}{c c c c c c c c c c c c c c c c c c c $ | |
| 10 Vitamin C tablets 14(23.3) 46(76.7) 17(10.6) 144(89.4) 24(21.6) 87(78.4) 17(25.4) 50(74.6) 2(25.0) 6(75 Physical 18.7 81.3 18.5 81.5 81.6 21.5 78.5 30.0 70.0 Physical Examination 1(1.7) 59(98.3) 6(3.7) 2(1.8) 109(98.2) 1(1.5) 66(98.5) 0(0.0) 8(10) 12 Breast examination 1(1.7) 59(98.3) 56(34.8) 105(65.2) 35(31.5) 76(68.5) 25(37.3) 42(62.7) 1(12.5) 7(87) 13 Examination of skin 40(66.7) 20(33.3) 71(44.1) 90(55.9) 47(42.3) 64(57.7) 39(58.2) 28(41.8) 6(75.0) 2(25 14 Examination of private part 43(71.7) 17(28.3) 70(43.5) 91(56.5) 50(45.0) 61(55.0) 40(59.7) 27(40.3) 6(75.0) 2(25 2(25.0) 6(75 2(25.0) 6(75 14 Examination of private part 43(71.7) 17(28.3) 70(43.5) 91(56.5) 50(45.0) 61(55.0) | 25.0) |
| 14(23.3) 46(76.7) 17(10.6) 144(89.4) 24(21.6) 87(78.4) 17(25.4) 50(74.6) 2(25.0) 6(75 Cluster % 18.7 81.3 18.5 18.4 81.6 21.5 78.5 30.0 70.0 Physical Examination 81.5 81.5 81.6 21.5 78.5 30.0 70.0 11 Abdominal palpation 1(1.7) 59(98.3) 6(3.7) 2(1.8) 109(98.2) 1(1.5) 66(98.5) 0(0.0) 8(1.0) 12 Breast examination 30(50.0) 30(50.0) 56(34.8) 105(65.2) 35(31.5) 76(68.5) 25(37.3) 42(62.7) 1(12.5) 7(87 13 Examination of skin 40(66.7) 20(33.3) 71(44.1) 90(55.9) 47(42.3) 64(57.7) 39(58.2) 28(41.8) 6(75.0) 2(25 14 Examination of private part 43(71.7) 17(28.3) 70(43.5) 91(56.5) 50(45.0) 61(55.0) 40(59.7) 27(40.3) 6(75.0) 2(25 15 HIV test 2(3.3) 58(96.7) 7(4.3) 154(95.7) | |
| Cluster % 18.7 81.3 18.5 18.4 81.6 21.5 78.5 30.0 70.0 Physical Examination 81.5 81.5 81.5 81.5 81.6 21.5 78.5 30.0 70.0 11 Abdominal palpation 1(1.7) 59(98.3) 6(3.7) 2(1.8) 109(98.2) 1(1.5) 66(98.5) 0(0.0) 8(10 12 Breast examination 30(50.0) 30(50.0) 56(34.8) 105(65.2) 35(31.5) 76(68.5) 25(37.3) 42(62.7) 1(12.5) 7(87 13 Examination of skin 40(66.7) 20(33.3) 71(44.1) 90(55.9) 47(42.3) 64(57.7) 39(58.2) 28(41.8) 6(75.0) 2(25 14 Examination of private part 43(71.7) 17(28.3) 70(43.5) 91(56.5) 50(45.0) 61(55.0) 40(59.7) 27(40.3) 6(75.0) 2(25 15 HIV test 2(3.3) 58(96.7) 7(4.3) 154(95.7) 7(6.3) 104(93.7) 3(4.5) 64(95.5) 0(0.0) 8(10 16 Urine test for protein and sugar < | (5.0) |
| Inviscal Examination S1.5 11 Abdominal palpation 1(1.7) 59(98.3) 6(3.7) 2(1.8) 109(98.2) 1(1.5) 66(98.5) 0(0.0) 8(10) 12 Breast examination 30(50.0) 30(50.0) 56(34.8) 105(65.2) 35(31.5) 76(68.5) 25(37.3) 42(62.7) 1(12.5) 7(87) 13 Examination of skin 40(66.7) 20(33.3) 71(44.1) 90(55.9) 47(42.3) 64(57.7) 39(58.2) 28(41.8) 6(75.0) 2(25) 14 Examination of private part 43(71.7) 17(28.3) 70(43.5) 91(56.5) 50(45.0) 61(55.0) 40(59.7) 27(40.3) 6(75.0) 2(25) Cluster % 47.5 52.5 31.5 68.5 30.2 69.8 39.2 60.8 40.6 594 15 HIV test 2(3.3) 58(96.7) 7(4.3) 154(95.7) 7(6.3) 104(93.7) 3(4.5) 64(95.5) 0(0.0) 8(10) 16 Urine test for protein and sugar 5(8.3) 55(91.7) 11(6.8) 150(93.2) 3(2.7) 108(97.3) | .0 |
| 11 Abdominal palpation 1(1.7) 59(98.3) 6(3.7) 2(1.8) 109(98.2) 1(1.5) 66(98.5) 0(0.0) 8(10) 12 Breast examination 30(50.0) 30(50.0) 56(34.8) 105(65.2) 35(31.5) 76(68.5) 25(37.3) 42(62.7) 1(12.5) 7(87) 13 Examination of skin 40(66.7) 20(33.3) 71(44.1) 90(55.9) 47(42.3) 64(57.7) 39(58.2) 28(41.8) 6(75.0) 2(25) 14 Examination of private part 43(71.7) 17(28.3) 70(43.5) 91(56.5) 50(45.0) 61(55.0) 40(59.7) 27(40.3) 6(75.0) 2(25) Cluster % 47.5 52.5 31.5 68.5 30.2 69.8 39.2 60.8 40.6 594 15 HIV test 2(3.3) 58(96.7) 7(4.3) 154(95.7) 7(6.3) 104(93.7) 3(4.5) 64(95.5) 0(0.0) 8(10) 16 Urine test for protein and sugar 5(8.3) 55(91.7) 11(6.8) 150(93.2) 3(2.7) 108(97.3) 10(14.9) 57(85.1) 2(25.0) | |
| palpation 1(1.7) 59(98.3) 6(3.7) 2(1.8) 109(98.2) 1(1.5) 66(98.5) 0(0.0) 8(10) 12 Breast examination 30(50.0) 30(50.0) 56(34.8) 105(65.2) 35(31.5) 76(68.5) 25(37.3) 42(62.7) 1(12.5) 7(87) 13 Examination of skin 40(66.7) 20(33.3) 71(44.1) 90(55.9) 47(42.3) 64(57.7) 39(58.2) 28(41.8) 6(75.0) 2(25) 14 Examination of private part private part 43(71.7) 17(28.3) 70(43.5) 91(56.5) 50(45.0) 61(55.0) 40(59.7) 27(40.3) 6(75.0) 2(25) 15 HIV test und sugar 2(3.3) 58(96.7) 7(4.3) 154(95.7) 7(6.3) 104(93.7) 3(4.5) 64(95.5) 0(0.0) 8(10) 16 Urine test for protein and sugar 5(8.3) 55(91.7) 11(6.8) 150(93.2) 3(2.7) 108(97.3) 10(14.9) 57(85.1) 2(25.0) 6(75.7) 17 Blood test for Start Start Start Start Start Start Start <th< th=""><td></td></th<> | |
| 12 Breast examination 30(50.0) 30(50.0) 56(34.8) 105(65.2) 35(31.5) 76(68.5) 25(37.3) 42(62.7) 1(12.5) 7(87) 13 Examination of skin 40(66.7) 20(33.3) 71(44.1) 90(55.9) 47(42.3) 64(57.7) 39(58.2) 28(41.8) 6(75.0) 2(25) 14 Examination of private part 43(71.7) 17(28.3) 70(43.5) 91(56.5) 50(45.0) 61(55.0) 40(59.7) 27(40.3) 6(75.0) 2(25) Cluster % 47.5 52.5 31.5 68.5 30.2 69.8 39.2 60.8 40.6 594 15 HIV test 2(3.3) 58(96.7) 7(4.3) 154(95.7) 7(6.3) 104(93.7) 3(4.5) 64(95.5) 0(0.0) 8(10) 16 Urine test for protein and sugar 5(8.3) 55(91.7) 11(6.8) 150(93.2) 3(2.7) 108(97.3) 10(14.9) 57(85.1) 2(25.0) 6(75.7) 17 Blood test for 55(91.7) 11(6.8) 150(93.2) 3(2.7) 108(97.3) 10(14.9) 57(85.1) 2(25.0) | (0.00 |
| 12 Breast examination 30(50.0) 30(50.0) 56(34.8) 105(65.2) 35(31.5) 76(68.5) 25(37.3) 42(62.7) 1(12.5) 7(87) 13 Examination of skin 40(66.7) 20(33.3) 71(44.1) 90(55.9) 47(42.3) 64(57.7) 39(58.2) 28(41.8) 6(75.0) 2(25) 14 Examination of private part 43(71.7) 17(28.3) 70(43.5) 91(56.5) 50(45.0) 61(55.0) 40(59.7) 27(40.3) 6(75.0) 2(25) Cluster % 47.5 52.5 31.5 68.5 30.2 69.8 39.2 60.8 40.6 594 15 HIV test 2(3.3) 58(96.7) 7(4.3) 154(95.7) 7(6.3) 104(93.7) 3(4.5) 64(95.5) 0(0.0) 8(10) 16 Urine test for protein and sugar 5(8.3) 55(91.7) 11(6.8) 150(93.2) 3(2.7) 108(97.3) 10(14.9) 57(85.1) 2(25.0) 6(75) 17 Blood test for 55(91.7) 11(6.8) 150(93.2) 3(2.7) 108(97.3) 10(14.9) 57(85.1) 2(25.0) | |
| $\begin{array}{c ccccccccccccccccccccccccccccccccccc$ | |
| 13 Examination of skin 40(66.7) 20(33.3) 71(44.1) 90(55.9) 47(42.3) 64(57.7) 39(58.2) 28(41.8) 6(75.0) 2(25 14 Examination of private part 43(71.7) 17(28.3) 70(43.5) 91(56.5) 50(45.0) 61(55.0) 40(59.7) 27(40.3) 6(75.0) 2(25 Cluster % 47.5 52.5 31.5 68.5 30.2 69.8 39.2 60.8 40.6 594 Screening 15 HIV test 2(3.3) 58(96.7) 7(4.3) 154(95.7) 7(6.3) 104(93.7) 3(4.5) 64(95.5) 0(0.0) 8(100) 16 Urine test for protein and sugar 5(8.3) 55(91.7) 11(6.8) 150(93.2) 3(2.7) 108(97.3) 10(14.9) 57(85.1) 2(25.0) 6(75.0) 17 Blood test for 55(91.7) 11(6.8) 150(93.2) 3(2.7) 108(97.3) 10(14.9) 57(85.1) 2(25.0) 6(75.7) | 57.5) |
| 14 Examination of private part 43(71.7) 17(28.3) 70(43.5) 91(56.5) 50(45.0) 61(55.0) 40(59.7) 27(40.3) 6(75.0) 2(25 2(25) Cluster % 47.5 52.5 31.5 68.5 30.2 69.8 39.2 60.8 40.6 594 15 HIV test 2(3.3) 58(96.7) 7(4.3) 154(95.7) 7(6.3) 104(93.7) 3(4.5) 64(95.5) 0(0.0) 8(10) 16 Urine test for protein and sugar 5(8.3) 55(91.7) 11(6.8) 150(93.2) 3(2.7) 108(97.3) 10(14.9) 57(85.1) 2(25.0) 6(75) 17 Blood test for 55(91.7) 11(6.8) 150(93.2) 3(2.7) 108(97.3) 10(14.9) 57(85.1) 2(25.0) 6(75) | 25 0) |
| International private part 43(71.7) 17(28.3) 70(43.5) 91(56.5) 50(45.0) 61(55.0) 40(59.7) 27(40.3) 6(75.0) 2(25 Cluster % 47.5 52.5 31.5 68.5 30.2 69.8 39.2 60.8 40.6 594 Screening 15 HIV test 2(3.3) 58(96.7) 7(4.3) 154(95.7) 7(6.3) 104(93.7) 3(4.5) 64(95.5) 0(0.0) 8(10 16 Urine test for protein and sugar 5(8.3) 55(91.7) 11(6.8) 150(93.2) 3(2.7) 108(97.3) 10(14.9) 57(85.1) 2(25.0) 6(75 17 Blood test for 50 50(91.7) 11(6.8) 150(93.2) 3(2.7) 108(97.3) 10(14.9) 57(85.1) 2(25.0) 6(75 | .5.0) |
| Cluster % 47.5 52.5 31.5 68.5 30.2 69.8 39.2 60.8 40.6 594 Screening 15 HIV test 2(3.3) 58(96.7) 7(4.3) 154(95.7) 7(6.3) 104(93.7) 3(4.5) 64(95.5) 0(0.0) 8(10) 16 Urine test for protein and sugar 5(8.3) 55(91.7) 11(6.8) 150(93.2) 3(2.7) 108(97.3) 10(14.9) 57(85.1) 2(25.0) 6(75) 17 Blood test for 10 100 | 25.0) |
| Screening Screening 15 HIV test 2(3.3) 58(96.7) 7(4.3) 154(95.7) 7(6.3) 104(93.7) 3(4.5) 64(95.5) 0(0.0) 8(10) 16 Urine test for protein and sugar 5(8.3) 55(91.7) 11(6.8) 150(93.2) 3(2.7) 108(97.3) 10(14.9) 57(85.1) 2(25.0) 6(75) 17 Blood test for 56 55(91.7) 11(6.8) 150(93.2) 3(2.7) 108(97.3) 10(14.9) 57(85.1) 2(25.0) 6(75) | 4 |
| 15 HIV test 2(3.3) 58(96.7) 7(4.3) 154(95.7) 7(6.3) 104(93.7) 3(4.5) 64(95.5) 0(0.0) 8(10) 16 Urine test for protein and sugar 5(8.3) 55(91.7) 11(6.8) 150(93.2) 3(2.7) 108(97.3) 10(14.9) 57(85.1) 2(25.0) 6(75) 17 Blood test for 50 10 | |
| 16 Urme test for protein and sugar 5(8.3) 55(91.7) 11(6.8) 150(93.2) 3(2.7) 108(97.3) 10(14.9) 57(85.1) 2(25.0) 6(75 17 Blood test for | .00.0) |
| 5(8.3) 55(91.7) 11(6.8) 150(93.2) 3(2.7) 108(97.3) 10(14.9) 57(85.1) 2(25.0) 6(75 17 Blood test for | |
| 17 Blood test for | 75.0) |
| | 5.0) |
| anaemia 8(13.3) 52(86.7) 13(8.1) 148(91.9) 8(7.2) 103(92.8) 12(17.9) 55(82.1) 2(25.0) 6(75 | (5.0) |
| 18 Blood test for | |
| malaria parasite | |
| 17(28.3) 43(71.7) 18(11.2) 143(88.8) 22(19.8) 89(80.2) 28(41.8) 39(58.2) 5(62.5) 3(37) 18(11.2) 1 | (7.5) |
| 19 BP measurement $2(2, 2) = 58(06, 7) = 2(1, 0) = 158(09, 1) = 4(2, 6) = 107(06, 4) = 1(1, 5) = 66(09, 5) = 0(0, 0) = 8(10, 6)$ | (00.0) |
| 2(5.5) $30(90.7)$ $5(1.5)$ $130(70.1)$ $4(5.0)$ $10(70.4)$ $1(1.5)$ $00(70.5)$ $0(0.0)$ $0(10)$ | .5 |
| Immunzation | |
| 20 TTI dose 1(1.7) 59(98.3) 4(2.5) 157(97.5) 5(4.5) 106(95.5) 13(19.4) 54(80.6) 4(50.0) 4(50.0) | ;0.0) |
| 21 TT2 dose 22(36.7) 38(63.3) 49(30.4) 112(69.6) 22(19.8) 89(80.2) 24(35.8) 43(64.2) 4(50.0) 4(50.0) | (0.0) |
| 22 TT3 dose $54(90.0)$ $6(10.0)$ $154(95.7)$ $7(4.3)$ $96(86.5)$ $15(13.5)$ $62(92.5)$ $57(.5)$ $6(75.0)$ $2(25)$ $5(7.5)$ $6(75.0)$ $2(75)$ $6(75)$ $2(75)$ $6(75)$ $2(75)$ $6(75)$ $2(75)$ $6(75)$ $2(75)$ $6(75)$ $2(7$ | (5.0) |
| 23 114 dose $60(100.0)$ $0(0.0)$ $160(99.4)$ $1(0.6)$ $109(98.2)$ $2(1.8)$ $67(100.0)$ $0(0.0)$ $8(100.0)$ $0(0.0)$ | 1(1) |
| 24 115 dose $60(100.0) 0(0.0) 159(98.8) 2(1.2) 106(95.5) 5(4.5) 55(82.1) 12(17.9) 4(50.0) 4(50.0) 1000 9(5.7) 201 (57.$ | |
| Cruster // 05.7 34.3 05.4 34.0 00.7 37.1 00.0 34.0 05.0 35 Overall % 28.6 71.4 24.6 75.4 23.9 76.1 28.9 71.1 33.3 66 | 50.0) 50.0) |

Table 2 shows that the overall per cent total of pregnant women within the age group of 46 years and above (33.3%) recorded the highest level of utilization of ANC services, followed by age group 33-45 years (28.9%), below 19 years (28.6) and 19-25 years (24.6%). In health education, age group 46 years and above (10.0%) recorded highest utilization followed by age group 33-45 years (3.9%), below 19 years (3.7%), 26-32 years (3.6%) while respondents within the age group of 19-25 (2.5%) recorded the lowest utilization. In routine drugs, age group 46 years and above (30.0%) recorded highest utilization followed by age group 33-45 years (21.5%), below 19 years (18.7%), 19-25 years (18.5%) while age group 26-32 years (18.4%) recorded lowest utilization. In physical examination, age group below 19 years (47.5%) followed by age group 46 years and above (40.6%), 33-45 years (39.2%), 19-25 years (31.5%) while age group 26-32 years (30.2%) recorded the lowest utilization. In screening, age group 46 years and above (22.5%) followed by age group 33-45 years (16.1%), below 19 years (11.3%), 26-32 years (7.9%) while age group 19-25 years (6.5%) recorded

the lowest. In immunization, age group 33-45 years (66.0%) recorded the highest utilization followed by age group below 19 years (65.7%), 19-25 years (65.4%), 46 years and above (65.0%) while age group 26-32 years (60.9%) recorded the lowest.

Table 3

| Pro | portion of Utilization of ANC Serv | vices Among Pregn | ant Women B | ased on Loca | ation (n=407) |
|-----|------------------------------------|-------------------|-------------|--------------|---------------|
| S/n | Location | Urban area | | Rural area | |
| | | (n =120) | | (n=287) | |
| | | Yes | No | Yes | No |
| | | f(%) | f(%) | f(%) | f(%) |
| | Health Education | | | | |
| 1 | Exclusive breast feeding | 0(0.0) | 120(100.0) | 13(4.5) | 274(95.5) |
| 2 | Nutrition | 2(1.7) | 118(98.3) | 7(2.4) | 280(97.6) |
| 3 | Family planning | 1(0.8) | 119(99.2) | 8(2.8) | 279(97.2) |
| 4 | Personal hygiene | 2(1.7) | 118(98.3) | 7(2.4) | 280(97.6) |
| 5 | Exercise | 2(1.7) | 118(98.3) | 26(9.1) | 261(90.9) |
| | Cluster % | 1.2 | 98.8 | 21.2 | 78.8 |
| | Routine Drugs | | | | |
| 6 | Ferrous sulphate | 0(0.0) | 120(100.0) | 5(1.7) | 282(98.3) |
| 7 | Folic acid | 0(0.0) | 120(100.0) | 20(7.0) | 267(93.0) |
| 8 | Multivitamin tablets | 2(1.7) | 118(98.3) | 14(4.9) | 273(95.1) |
| 9 | Vitamin B complex | 84(70.0) | 36(30.0) | 192(66.9) | 95(33.1) |
| 10 | Vitamin C tablets | 14(11.7) | 106(88.3) | 60(20.9) | 227(79.1) |
| | Cluster % | 16.7 | 83.3 | 20.3 | 79. 7 |
| | Physical Examination | | | | |
| 11 | Abdominal palpation | 2(1.7) | 118(98.3) | 8(2.8) | 279(97.2) |
| 12 | Breast examination | 50(41.7) | 70(58.3) | 97(33.8) | 190(66.2) |
| 13 | Examination of skin | 57(47.5) | 63(52.5) | 146(50.9) | 141(49.1) |
| 14 | Examination of private part | 58(48.3) | 62(51.7) | 151(52.6) | 136(47.4) |
| | Cluster % | 34.8 | 65.2 | 35.0 | 65.0 |
| | Screening | | | | |
| 15 | HIV test | 3(2.5) | 117(97.5) | 16(5.6) | 271(94.4) |
| 16 | Urine test for protein and sugar | 2(1.7) | 118(98.3) | 29(10.1) | 258(89.9) |
| 17 | Blood test for anaemia | 4(3.3) | 116(96.7) | 39(13.6) | 248(86.4) |
| 18 | Blood test for malaria parasite | 11(9.2) | 109(90.8) | 79(27.5) | 208(72.5) |
| 19 | BP measurement | 1(0.8) | 119(99.2) | 9(3.1) | 278(96.9) |
| | Cluster % | 3.5 | 96.5 | 12.0 | 88.0 |
| | Immunization | | | | |
| 20 | TT1 dose | 6(5.0) | 114(95.0) | 21(7.3) | 266(92.7) |
| 21 | TT2 dose | 31(25.8) | 89(74.2) | 90(31.4) | 197(68.6) |
| 22 | TT3 dose | 111(92.5) | 9(7.5) | 261(90.9) | 26(9.1) |
| 23 | TT4 dose | 118(98.3) | 2(1.7) | 286(99.7) | 1(0.3) |
| 24 | TT5 dose | 114(95.0) | 6(5.0) | 270(94.1) | 17(5.9) |
| | Cluster % | 63.3 | 36.7 | 64.7 | 35.3 |
| | Overall % | 23.4 | 76.6 | 26.9 | 73.1 |

Table 3 shows the overall total of pregnant women in rural area (26.9%) utilized ANC services than their counterparts in the urban area (23.4%). In health education, respondents in rural area (21.2%) recorded highest utilization followed by those in urban area (1.2%). In routine drugs, pregnant women in rural area (20.3%) recorded highest utilization while those in urban area (16.7%) recorded the lowest utilization. In physical examination, respondents at rural areas (35.0%) recorded highest utilization. In screening, the highest utilization is recorded among respondents in rural area (12.0%) while those in urban area (3.5%) recorded the lowest utilization. In immunization, respondents in rural area (64.7%) recorded highest utilization while respondents in urban area (63.3%) recorded the lowest utilization.

Proportion of Utilization of ANC Services Among Pregnant Women Based on Parity (n=407)

Table 4

| S/n | Parity | 1-2 childre | en | 3-4 childre | en | 5 children | & above | first pregn | ancy |
|-----|------------------|-------------|--------------------|-------------|-------------|------------|-----------|-------------|------------------|
| | | (n=148) | | (n =114) | | (n=52) | | (n =93) | |
| | | Yes | No | Yes | No | Yes | No | Yes | No |
| | | f(%) | f(%) | f(%) | f(% | f(%) | f(%) | f(%) | f(%) |
| | Health | | | | | | | | |
| 1 | Education | | | | | | | | |
| | Exclusive breast | 3(2.0) | 145(98.0) | 4(3.5) | 110(96.5) | 3(5.8) | 49(94.2) | 3(3.2) | 90(96.8) |
| • | feeding | 2(2.0) | 145(00.0) | 2(1.0) | 112(00.0) | 1(1.0) | 51(00.1) | | 00(0 < 0) |
| 2 | Nutrition | 3(2.0) | 145(98.0) | 2(1.8) | 112(98.2) | 1(1.9) | 51(98.1) | 3(3.2) | 90(96.8) |
| 3 | Family planning | 2(1.4) | 146(98.6) | 2(1.8) | 112(98.2) | 3(5.8) | 49(94.2) | 2(2.2) | 91(97.8) |
| 4 | Personal | 3(2.0) | 145(98.0) | 2(1.8) | 112(98.2) | 1(1.9) | 51(98.1) | 3(3.2) | 90(96.8) |
| 5 | Evercise | 8(5.4) | 1/0(9/ 6) | 10(8.8) | 104(91.2) | 5(9.6) | 47(90.4) | 5(5.4) | 88(04.6) |
| 5 | Cluster % | 26 | 07 <i>1</i> | 35 | 06 5 | 50 | 95.0 | 31 | 06 6 |
| | Routine Drugs | 2.0 | <i>71.</i> 4 | 5.5 | 90.5 | 5.0 | 93.0 | 3.4 | 90.0 |
| 6 | Ferrous | 0(0, 0) | 148(100.0) | 4(3.5) | 110(96.5) | 0(0, 0) | 52(100.0) | 1(1.1) | 92(98.9) |
| 0 | sulphate | 0(0.0) | 140(100.0) | ч(3.3) | 110(90.5) | 0(0.0) | 52(100.0) | 1(1.1) |)2()0.)) |
| 7 | Folic acid | 3(2.0) | 145(98.0) | 7(6.1) | 107(93.9) | 7(13.5) | 45(86.5) | 3(3.2) | 90(96.8) |
| 8 | Multivitamin | 3(2.0) | 145(98.0) | 6(5.3) | 108(94.7) | 4(7.7) | 48(92.3) | 3(3.2) | 90(96.8) |
| | tablets | | · · · · | | × , | | | | . , |
| 9 | Vitamin B | 100(67.6) | 48(32.4) | 73(64.0) | 41(36.0) | 31(59.6) | 21(40.4) | 72(77.4) | 21(22.6) |
| | complex | | | | | | | | |
| 10 | Vitamin C | 17(11.5) | 131(88.5) | 27(23.7) | 87(76.3) | 16(30.8) | 36(69.2) | 14(15.1) | 79(84.9) |
| | tablets | | | | | | | | |
| | Cluster % | 16.6 | 83.4 | 20.5 | 79.5 | 22.3 | 77.7 | 20.0 | 80.0 |
| | Physical | | | | | | | | |
| | Examination | | | | | | | | |
| 11 | Abdominal | | | | | | | | |
| | palpation | 2(1.4) | 146(98.6) | 6(5.3) | 108(94.7) | 0(0.0) | 52(100.0) | 2(2.2) | 91(97.8) |
| 12 | Breast | 8(39.2) | 90(60.8) | 52(45.6) | 62(54.4) | 10(19.2) | 42(80.8) | 27(29.0) | 66(71.0) |
| | examination | | | | | | | | |
| 13 | Examination of | 73(49.3) | 75(50.7) | 72(63.2) | 42(36.8) | 25(48.1) | 27(51.9) | 33(35.5) | 60(64.5) |
| 14 | SKIN | | | | | | | | |
| 14 | Examination of | 74(50.0) | 74(50.0) | 72(62.2) | 12(2(9) | 2((50,0)) | 2((50,0)) | 27(20.9) | 50(00 2) |
| | Christian 9/ | 74(50.0) | 74(50.0) | 12(03.2) | 42(30.8) | 20(50.0) | 20(50.0) | 37(39.8) | 50(00.2) 72.2 |
| | Cluster 70 | 55.0 | 05.0 | 44.5 | 55.7 | 39.3 | /0./ | 20.0 | /5.5 |
| 15 | HIV test | A(2,7) | 144(07.3) | 8(7.0) | 106(03.0) | 3(5.8) | 40(04.2) | A(A 3) | 80(05.7) |
| 15 | Urine test for | 4(2.7) | 144(97.3) | 8(7.0) | 100(95.0) | 3(3.8) | 49(94.2) | 4(4.3) | 89(95.7) |
| 10 | protein and | 12(8.1) | 136(91.9) | 10(8.8) | 104(91.2) | 5(9.6) | 47(90.4) | $4(4 \ 3)$ | 89(95.7) |
| | sugar | 12(0.1) | 150(51.5) | 10(0.0) | 104()1.2) | 5(5.0) | 47(50.4) | -(-1.5) | 0)()).() |
| 17 | Blood test for | | | | | | | | |
| 17 | anaemia | 17(11.5) | 131(88.5) | 13(11.4) | 101(88.6) | 6(11.5) | 46(88.5) | 7(7.5) | 86(92.5) |
| 18 | Blood test for | 17(110) | 101(0010) | 10(111) | 101(0010) | 0(1110) | | /(/10) | 00()=10) |
| | malaria parasite | 21(14.2) | 127(85.8) | 31(27.2) | 83(72.8) | 23(44.2) | 29(55.8) | 15(16.1) | 78(83.9) |
| 19 | BP | 2(1.4) | 146(98.6) | 3(2.6) | 111(97.4) | 2(3.8) | 50(96.2) | 3(3.2) | 90(96.8) |
| | measurement | × / | | | . , | | . , | | . , |
| | Cluster % | 7.6 | 92.4 | 11.4 | 88.6 | 15.0 | 85.0 | 7.1 | 92.9 |
| | Immunization | | | | | | | | |
| 20 | TT1 dose | 3(2.0) | 145(98.0) | 10(8.8) | 104(91.2) | 12(23.1) | 40(76.9) | 2(2.2) | 91(97.8) |
| 21 | TT2 dose | 31(20.9) | 117(79.1) | 39(34.2) | 75(65.8) | 15(28.8) | 37(71.2) | 36(38.7) | 57(61.3) |
| 22 | TT3 dose | 140(94.6) | 8(5.4) | 99(86.8) | 15(13.2) | 46(88.5) | 6(11.5) | 87(93.5) | 6(6.5) |
| 23 | TT4 dose | 147(99.3) | 1(0.7) | 112(98.2) | 2(1.8) | 52(100.0) | 0(0.0) | 93(100.0) | 0(0.0) |
| 24 | TT5 dose | 146(98.6) | 2(1.4) | 105(92.1) | 9(7.9) | 41(78.8) | 11(21.2) | 92(98.9) | 1(1.1) |
| | Cluster % | 63.1 | 36.9 | 64.0 | 36.0 | 63.8 | 36.2 | 66.7 | 33.3 |
| | Overall % | 24.5 | 75.5 | 28.1 | 71.9 | 27.0 | 73.0 | 24.7 | 75.3 |

Table 4 shows the overall per cent total of level of utilization of ANC services among pregnant women. Respondents who have 3-4 children (28.1%) recorded the highest followed by those who have 5 children and above (27.0%) and pregnant women with first pregnancy (24.7), while pregnant women 1-2 children (24.5%) recorded the lowest utilization. In health education, the highest utilization was recorded among respondents with 5 children and above (5.0%) followed by those with 3-4 children (3.5%), first pregnancy (3.4%) while respondents with 1-2 children (2.6%) recorded the

lowest utilization. In routine drugs, the highest utilization was recorded among respondents with 5 children and above (22.3%) followed by those with 3-4 children (20.5%), first pregnancy (20.0%) and respondents with 1-2 children (16.6%) recorded the lowest utilization. In physical examination, pregnant women with 3-4 children (44.3%) recorded the highest utilization followed by those with 5 children and above (39.3%), 1-2 children (35.0%) and those with first pregnancy (26.6%) recorded the lowest utilization. In screening, respondents with 5 children and above (15.0%) recorded the highest utilization followed by those with 3-4 children (11.4%), 1-2 children (7.6%) while respondents with first pregnancy (66.7%) recorded the highest followed by respondents with 3-4 children (64.0%); 5 children and above (63.8%) while respondents with 1-2 children (63.1%) recorded the lowest utilization

Table 5

| Summary of Chi-square (χ^2) | Analysis Testing | the Null hypothe | sis of no s | significant | difference in |
|----------------------------------|-------------------------|------------------|-------------|-------------|---------------|
| the utilization of ANC service | es among pregnai | nt women based o | n age | | |

| S/n | Age | Below 19 years 19 – 25 years | | | | | 26 – 32 years 33 – 45 years | | | | | | | | ars 46 yrs & above | | | | | χ^2 | D | Sig. | | |
|---------|-------------------|------------------------------|-------|------------|------|---------|-----------------------------|-----|-------|-------|---------------|----------|--------------|-------|--------------------|------------|----------------------------|-----|-----|----------|-----|--------|----------|------|
| | | (r | 1=60) | | | (n=161) | | | (n | =111) | | | (1 | n=67) | | | (n | =8) | | | | f | Р | |
| | | Ν | 0 | Y | es | N | D | Yes | | N | 0 | Yes | ; | N | lo | Y | es | No |) | Y | es | - | | |
| | | | | | | | | | | | | | | | | | | | | | | | | |
| | | 0 | e | 0 | e | 0 | e | 0 | e | 0 | e | 0 | e | 0 | e | 0 | e | 0 | e | 0 | e | | | |
| | Health | | | | | | | | | | | | | | | | | | | | | | | |
| 1 | Education | | | | | | | | | | | | | | | | | | | | | | | |
| | Exclusive breast | 2 | 1.9 | 58 | 58.1 | 3 | 5.1 | 158 | 155.9 | 2 | 3.5 | 109 | 107.5 | 5 | 2.1 | 62 | 64.9 | 1 | .3 | 7 | 7.7 | 7.810 | 4 | .099 |
| | feeding | | | | | | | | | | | | | | | | | | | _ | | | | |
| 2 | Nutrition | 2 | 1.3 | 58 | 58.7 | 3 | 3.6 | 158 | 157.7 | 3 | 2.5 | 108 | 108.5 | 1 | 1.5 | 66 | 65.5 | 0 | .2 | 8 | 7.8 | .904 | 4 | .924 |
| 3 | Family planning | 1 | 1.3 | 59 | 58,7 | 3 | 3.6 | 158 | 157.4 | 2 | 2.5 | 109 | 108.5 | 2 | 1.5 | 65 | 65.5 | 1 | .2 | 7 | 7.8 | 4.360 | 4 | .359 |
| 4 | Personal hygiene | 3 | 1.3 | 57 | 58.7 | 2 | 3.6 | 159 | 157.4 | 3 | 2.5 | 108 | 108.5 | 1 | 1.5 | 66 | 65.5 | 0 | .2 | 8 | 7.8 | 3.322 | 4 | .505 |
| 5 | Exercise | 3 | 4.1 | 57 | 55.9 | 9 | 11.1 | 152 | 149.9 | 10 | 7.6 | 101 | 103.4 | 4 | 4.6 | 63 | 62.4 | 2 | .6 | 6 | 7.4 | 5.721 | 4 | .221 |
| | Cluster Value | | | | | | | | | | | | | | | | | | | | | 31.757 | 10 | .011 |
| | Routine Drugs | 0 | 7 | <i>c</i> 0 | 50.2 | 2 | 2.0 | 150 | 150.0 | 2 | 1.4 | 100 | 100.4 | 1 | 0 | ~ | (()) | 0 | 1 | 0 | 7.0 | 1 105 | 4 | 001 |
| 0 | Ferrous sulphate | 0 | ./ | 60 | 59.5 | 2 | 2.0 | 159 | 159.0 | 2 | 1.4 | 109 | 109.4 | 1 | .8 | 60 | 62.7 | 2 | .1 | 8 | 7.9 | 1.185 | 4 | .881 |
| / | Polic aciu | 0 | 2.9 | 50 | 57.1 | 0 | 1.9 | 155 | 155.1 | 2 | 5.5 | 100 | 105.5 | 4 | 3.5 | 60 | 65.7 | 2 | .4 | 0 | 7.0 | 14.923 | 4 | .005 |
| 0 | Multivitamin tab | 2 | 2.4 | 20 | 57.0 | 0 | 0.3 | 155 | 154.7 | 2 | 4.4 | 109 | 25 7 | 4 | 2.0 | 0.5 | 04.4 | 2 | .5 | 0 | 1.1 | 11.548 | 4 | .021 |
| 9 10 | Vitamin C tablata | 40 | 40.7 | 20 | 19.5 | 110 | 20.2 | 45 | 121.7 | 24 | 20.2 | 42 97 | 55.7 00.8 | 45 | 43.4 | 24 | 21.0 54.9 | 2 | 3.4 | 6 | 2.0 | 4.409 | 4 | .340 |
| 10 | Chester Value | 14 | 10.9 | 40 | 47.1 | 17 | 29.5 | 144 | 151.7 | 24 | 20.2 | 07 | 90.8 | 17 | 12.2 | 80 | 54.0 | 2 | 1.5 | 0 | 0.5 | 20.411 | 12 | .029 |
| | Physical | | | | | | | | | | | | | | | | | | | | | 20.411 | 12 | .000 |
| 11 | Examination | 1 | 15 | 59 | 58.5 | 6 | 4.0 | 155 | 157.0 | 2 | 27 | 109 | 108.3 | 1 | 16 | 66 | 65.4 | 0 | 2 | 8 | 78 | 1 900 | 4 | 754 |
| 11 | Abdominal | • | 1.5 | 57 | 50.5 | 0 | 4.0 | 155 | 157.0 | 2 | 2.7 | 107 | 100.5 | | 1.0 | 00 | 05.4 | 0 | .2 | 0 | 7.0 | 1.900 | - | .754 |
| | palpation | | | | | | | | | | | | | | | | | | | | | | | |
| 12 | Breast | 30 | 21.7 | 30 | 39.3 | 56 | 58.1 | 105 | 102.9 | 35 | 40.1 | 76 | 70.9 | 25 | 24.2 | 42 | 42.8 | 1 | 2.9 | 7 | 5.1 | 8.123 | 4 | .087 |
| | examination | | | | | | | | | | | | | | | | | - | | | | 01120 | - | |
| 13 | Examination of | 40 | 29.9 | 20 | 30.1 | 71 | 80.3 | 90 | 80.7 | 47 | 55.4 | 64 | 55.6 | 39 | 33.4 | 28 | 33.6 | 6 | 4.0 | 2 | 4.0 | 15.316 | 4 | .004 |
| | skin | | | | | | | | | | | | | | | | | | | | | | | |
| 14 | Examination of | | | | | | | | | | | | | | | | | | | | | | | |
| | private part | 43 | 30.8 | 17 | 29.2 | 70 | 82.7 | 91 | 78.3 | 50 | 57.0 | 61 | 54.0 | 40 | 34.4 | 27 | 32.6 | 6 | 4.1 | 2 | 3.9 | 19.335 | 4 | .001 |
| | Cluster Value | | | | | | | | | | | | | | | | | | | | | 38.283 | 12 | .000 |
| | Screening | | | | | | | | | | | | | | | | | | | | | | | |
| 15 | HIV test | 2 | 2.8 | 58 | 57.2 | 7 | 7.5 | 154 | 153.5 | 7 | 5.2 | 104 | 105.8 | 3 | 3.1 | 64 | 63.9 | 0 | .4 | 8 | 7.6 | 1.344 | 4 | .854 |
| 16 | Urine T. for | | | | | | | | | | | | | | | | | | | | | | | |
| | protein and sugar | 5 | 4.6 | 55 | 55.4 | 11 | 12.3 | 150 | 148.8 | 3 | 8.5 | 108 | 102.5 | 10 | 5.1 | 57 | 61.9 | 2 | .6 | 6 | 7.4 | 12.515 | 4 | .014 |
| 17 | Blood test for | 8 | 6.3 | 52 | 53.7 | 13 | 17.0 | 148 | 144.0 | 8 | 11.7 | 103 | 99.3 | 12 | 7.1 | 55 | 59.9 | 2 | .8 | 6 | 7.2 | 8.458 | 4 | .076 |
| | anaemia | | | | | | | | | | | | | | | | | | | | | | | |
| 18 | Blood test for | 17 | 13.3 | 43 | 46.7 | 18 | 35.6 | 143 | 125.4 | 22 | 24.5 | 89 | 86.5 | 28 | 14.8 | 39 | 52.2 | 5 | 1.8 | 3 | 6.2 | 35.500 | 4 | .000 |
| | malaria p. | | | | | | | | | | | | | | | | | | | | | | | |
| 19 | BP measurement | 2 | 1.5 | 58 | 58.5 | 3 | 4.0 | 158 | 157.0 | 4 | 2.7 | 107 | 108.3 | 1 | 1.6 | 66 | 65.4 | 0 | .2 | 8 | 7.8 | 1.499 | 4 | .827 |
| | Cluster Value | | | | | | | | | | | | | | | | | | | | | 48.167 | 16 | .000 |
| | Immunization | 1 | 4.0 | 50 | 56.0 | 4 | 10.7 | 157 | 150.0 | F | 7.4 | 105 | 102 - | 12 | 4.4 | <i>E</i> 4 | <i>(</i>) <i>(</i> | 4 | F | | 7.5 | 10 505 | 4 | 000 |
| 20 | TTD dose | 1 | 4.0 | 59 20 | 56.0 | 4 | 10.7 | 15/ | 150.3 | 5 | 1.4 | 106 | 105.6 | 15 | 4.4 | 54 | 62.6 | 4 | .5 | 4 | 1.5 | 49.606 | 4 | .000 |
| 21 | 112 dose | 22 | 17.8 | 58 6 | 42.2 | 49 | 4/.9 | 112 | 115.1 | 22 | 55.0 101.5 | 89 | /8.0 | 24 | 19.9 | 45 | 4/.1 5 0 | 4 | 2.4 | 4 | 5.6 | 9.402 | 4 | .052 |
| 22 | TT4 dose | 54 | 54.8 | 0 | 3.2 | 154 | 147.2 | / | 13.8 | 90 | 101.5 | 15 | 9.5 0 | 62 | 01.2 | 5 | 5.8 | 0 | 7.5 | 2 | ./ | 2 752 | 4 | .039 |
| 23 | TT5 dose | 60 | 56.6 | 0 | .4 | 100 | 151.0 | 1 | 1.2 | 109 | 104.7 | 2 5 | .0 6.2 | 55 | 62.2 | 12 | .5 | 0 | 7.9 | 4 | .1 | 2.132 | 4 | .000 |
| 24 | Cluster Value | 00 | 20.0 | 0 | 3.4 | 159 | 151.9 | 4 | 7.1 | 100 | 104.7 | 5 | 0.5 | 55 | 05.2 | 12 | 3.0 | 4 | 1.5 | 4 | .3 | 25 809 | 4 20 | 172 |
| | Cluster value | | | | | | | | | | | | | | | | | | | | | 25.808 | 20 16 | .1/2 |
| | Overall value | | | | | | | | | | | | | | | | | | | | | 35.598 | 10 | .005 |

Cal χ^2 35.598, P value =.003, df =16, P <.05

Table 5 the X^2 calculated value of 35.598 with corresponding P-value of .003 which is less than .05 level of significance at 16 degree of freedom. The null hypothesis of no significant difference

in the utilization of ANC services among pregnant women based on age is therefore rejected. This means that utilization of ANC services differ significantly based on age.

Table 6

Summary of Chi-square (χ^2) Analysis Testing the Null hypothesis of no significant difference in the utilization of ANC services among pregnant women based on location

| S/n | Location | Urba | n area (| n=120) |) | Rura | l area (r | Value | Df | Sig. P | | |
|-----|---------------------------------|------|----------|--------|-------|------|-----------|-------|-------|--------|---|------|
| | | No | | Yes | | No | | Yes | | | | |
| | | 0 | e | 0 | e | 0 | e | 0 | e | | | |
| | Health Education | - | | | | | | - | | | | |
| 1 | Exclusive breast feeding | 0 | 3.8 | 120 | 116.2 | 13 | 9.2 | 274 | 277.8 | 5.615 | 1 | .018 |
| 2 | Nutrition | 2 | 2.7 | 118 | 117.3 | 7 | 6.3 | 280 | 280.7 | .233 | 1 | .629 |
| 3 | Family planning | 1 | 2.7 | 119 | 117.3 | 8 | 6.3 | 279 | 280.7 | 1.494 | 1 | .222 |
| 4 | Personal hygiene | 2 | 2.7 | 118 | 117.3 | 7 | 6.3 | 280 | 280.7 | .233 | 1 | .629 |
| 5 | Exercise | 2 | 8.3 | 118 | 111.7 | 26 | 19.7 | 261 | 267.3 | 7.219 | 1 | .007 |
| | Cluster Value | | | | | | | | | 19.826 | 4 | .001 |
| | Routine Drugs | | | | | | | | | | | |
| 6 | Ferrous sulphate | 0 | 1.5 | 120 | 118.5 | 5 | 3.5 | 282 | 283.5 | 2.117 | 1 | .146 |
| 7 | Folic acid | 0 | 5.9 | 120 | 114.1 | 20 | 14.1 | 267 | 272.9 | 8.795 | 1 | .003 |
| 8 | Multivitamin tab | 2 | 4.7 | 118 | 115.3 | 14 | 11.3 | 273 | 275.7 | 2.311 | 1 | .128 |
| 9 | Vitamin Bco | 84 | 81.4 | 36 | 38.6 | 192 | 194.6 | 95 | 92.4 | .373 | 1 | .541 |
| 10 | Vitamin C tablets | 14 | 21.8 | 106 | 98.2 | 60 | 52.2 | 227 | 234.8 | 4.856 | 1 | .028 |
| | Cluster Value | | | | | | | | | 8.272 | 3 | .041 |
| | Physical Examination | | | | | | | | | | | |
| 11 | Abdominal palpation | 2 | 2.9 | 118 | 117.1 | 8 | 7.1 | 279 | 279.9 | .444 | 1 | .505 |
| 12 | Breast examination | 50 | 43.3 | 70 | 76.7 | 97 | 103.7 | 190 | 183.3 | 2.271 | 1 | .132 |
| 13 | Examination of skin | 57 | 59.9 | 63 | 60.1 | 146 | 143.1 | 141 | 143.1 | .385 | 1 | .535 |
| 14 | Examination of private part | 58 | 61.6 | 62 | 58.4 | 151 | 147.4 | 136 | 139.6 | .620 | 1 | .431 |
| | Cluster Value | | | | | | | | | 6.172 | 3 | .104 |
| | Screening | | | | | | | | | | | |
| 15 | HIV test | 3 | 5.6 | 117 | 114.4 | 16 | 13.4 | 271 | 273.6 | 1.798 | 1 | .180 |
| 16 | Urine T. for protein and sugar | 2 | 9.1 | 118 | 110.9 | 29 | 21.9 | 258 | 265.1 | 8.562 | 1 | .003 |
| 17 | Blood test for anaemia | 4 | 12.7 | 116 | 107.3 | 39 | 30.3 | 248 | 256.7 | 9.419 | 1 | .002 |
| 18 | Blood test for malaria parasite | 11 | 26.5 | 109 | 93.5 | 79 | 63.5 | 208 | 223.5 | 16.561 | 1 | .000 |
| 19 | BP measurement | 1 | 2.9 | 119 | 117.1 | 9 | 7.1 | 278 | 279.9 | 1.872 | 1 | .171 |
| | Cluster Value | | | | | | | | | 23.419 | 4 | .000 |
| | Immunization | | | | | | | | | | | |
| 20 | TT1 dose | 6 | 8.0 | 114 | 112.0 | 21 | 19.0 | 266 | 268.0 | .733 | 1 | .392 |
| 21 | TT2 dose | 31 | 35.7 | 89 | 84.3 | 90 | 85.3 | 197 | 201.7 | 1.237 | 1 | .266 |
| 22 | TT3 dose | 111 | 109.7 | 9 | 10.3 | 261 | 262.3 | 26 | 24.7 | .262 | 1 | .609 |
| 23 | TT4 dose | 118 | 119.1 | 2 | .9 | 286 | 284.9 | 1 | 2.1 | 2.010 | 1 | .156 |
| 24 | TT5 dose | 114 | 113.2 | 6 | 6.8 | 270 | 270.8 | 17 | 16.2 | .135 | 1 | .713 |
| | Cluster Value | | | | | | | | | 6.170 | 5 | .290 |
| | Overall Value | | | | | | | | | 32.278 | 4 | .000 |

Cal χ^2 32.278, P value =.000, df =4, P <.05

Table 6 show the X^2 calculated value of 32.278 with corresponding P-value of .000 which is less than .05 level of significance at 4 degree of freedom. The null hypothesis of no significant difference in the utilization of ANC services among pregnant women based on location is therefore rejected. This means that utilization of ANC services differ significantly based on location.

Table 7

Summary of Chi-square (χ^2) Analysis Testing the Null hypothesis of no significant difference in the utilization of ANC services among pregnant women based on parity

| S/n | Parity | 1-2 | children (| n=148 |) | 3-4 children (n =114) | | | | 5 children & above (n=52) | | | | firs | st pregn | ancy(1 | 1 =93) | Value | Df | Sig. |
|-----|----------------------|----------|--------------|-------|------------|-----------------------|-------|--------|-------------|---------------------------|--------------|-----|----------|----------|-------------------|----------|----------|--------|----|-------------|
| | | No |) | Ye | s | No |) | Ye | s | No | | Yes | | No | | Ye | s | _ | | Р |
| | | _ | | | | | | | | | | | | | | | | | | |
| | H M FL C | 0 | e | 0 | e | 0 | e | 0 | e | 0 | e | 0 | e | 0 | e | 0 | e | | | |
| | Health Education | 2 | 47 | 145 | 142.2 | 4 | 26 | 110 | 110.4 | 2 | 17 | 40 | 50.2 | 2 | 2.0 | 00 | 00.0 | 1 004 | 2 | <i>c</i> 14 |
| 1 | Exclusive breast | 3 | 4.7 | 145 | 145.5 | 4 | 3.0 | 110 | 110.4 | 3 | 1.7 | 49 | 50.5 | 3 | 3.0 | 90 | 90.0 | 1.804 | 3 | .014 |
| 2 | Nutrition | 3 | 33 | 145 | 144 7 | 2 | 2.5 | 112 | 1115 | 1 | 1.1 | 51 | 50.9 | 3 | 21 | 90 | 90.9 | 596 | 3 | 897 |
| 3 | Family planning | 2 | 33 | 145 | 144.7 | 2 | 2.5 | 112 | 111.5 | 3 | 1.1 | 49 | 50.9 | 2 | 2.1 | 91 | 90.9 | 3 662 | 3 | 300 |
| 4 | Personal hygiene | 3 | 33 | 145 | 144.7 | 2 | 2.5 | 112 | 111.5 | 1 | 1.1 | 51 | 50.9 | 3 | 2.1 | 90 | 90.9 | 596 | 3 | 897 |
| 5 | Exercise | 8 | 10.2 | 140 | 137.8 | 10 | 7.8 | 104 | 106.2 | 5 | 3.6 | 47 | 48.4 | 5 | 6.4 | 88 | 86.4 | 2.075 | 3 | .557 |
| | Cluster Value | | | | | | | | | - | | | | | | | | 15.044 | 12 | .239 |
| | Routine Drugs | | | | | | | | | | | | | | | | | | | |
| 6 | Ferrous sulphate | 0 | 1.8 | 148 | 146.2 | 4 | 1.4 | 110 | 112.6 | 0 | .6 | 52 | 51.4 | 1 | 1.1 | 92 | 91.9 | 7.391 | 3 | .060 |
| 7 | Folic acid | 3 | 7.3 | 145 | 140.7 | 7 | 5.6 | 107 | 108.4 | 7 | 2.6 | 45 | 49.4 | 3 | 4.6 | 90 | 88.4 | 11.705 | 3 | .008 |
| 8 | Multivitamin tab | 3 | 5.8 | 145 | 142.2 | 6 | 4.5 | 108 | 109.5 | 4 | 2.0 | 48 | 50.0 | 3 | 3.7 | 90 | 89.3 | 4.027 | 3 | .259 |
| 9 | Vitamin Bco | 100 | 100.4 | 48 | 47.6 | 73 | 77.3 | 41 | 36.7 | 31 | 35.3 | 21 | 16.7 | 72 | 63.1 | 21 | 29.9 | 6.282 | 3 | .099 |
| 10 | Vitamin C tablets | 17 | 26.9 | 131 | 121.1 | 27 | 20.7 | 87 | 93.3 | 16 | 9.5 | 36 | 42.5 | 14 | 16.9 | 79 | 76.1 | 12.930 | 3 | .005 |
| | Cluster Value | | | | | | | | | | | | | | | | | 32.201 | 9 | .000 |
| | Physical | | | | | | | | | _ | | | | _ | | | | | _ | |
| 11 | Examination | 2 | 3.6 | 146 | 144.4 | 6 | 2.8 | 108 | 112.1 | 0 | 1.3 | 52 | 50.7 | 2 | 2.3 | 91 | 90.7 | 5.847 | 3 | .119 |
| | Abdominal palpation | 50 | 52.5 | 00 | 04.5 | 50 | 41.2 | (2) | 72.0 | 10 | 10.0 | 10 | 22.2 | 27 | 22.6 | ~ | 50.4 | 12 511 | 2 | 004 |
| 12 | Breast examination | 38 72 | 33.3 72.9 | 90 | 94.5 | 52 | 41.2 | 42 | 12.8 | 10 | 18.8 | 42 | 35.2 | 27 | 33.0 | 60 | 59.4 | 15.511 | 3 | .004 |
| 13 | Examination of skin | 73 | 75.8 | 75 | 74.2 | 72 | 58.5 | 42 | 57.1 | 25 | 25.9 | 27 | 20.1 | 33 27 | 40.4 | 00 56 | 40.0 | 15.855 | 3 | .001 |
| 14 | privoto port | /4 | 70.0 | /4 | 72.0 | 12 | 58.5 | 42 | 55.5 | 20 | 20.7 | 20 | 23.3 | 57 | 47.0 | 50 | 43.2 | 11.400 | 5 | .009 |
| | Cluster Value | | | | | | | | | | | | | | | | | 27 488 | 9 | 001 |
| | Screening | | | | | | | | | | | | | | | | | 27.400 | , | .001 |
| 15 | HIV test | 4 | 6.9 | 144 | 141.1 | 8 | 5.3 | 106 | 108.7 | 3 | 2.4 | 49 | 49.6 | 4 | 4.3 | 89 | 88.7 | 2.868 | 3 | .412 |
| 16 | Urine T. for protein | 12 | 11.3 | 136 | 136.7 | 10 | 8.7 | 104 | 105.5 | 5 | 4.0 | 47 | 48.0 | 4 | 7.1 | 89 | 85.9 | 2.015 | 3 | .569 |
| | and sugar | | | | | | | | | | | | | | | | | | | |
| 17 | Blood test for | 17 | 15.6 | 131 | 132.4 | 13 | 12.0 | 101 | 102.0 | 6 | 5.5 | 46 | 46.5 | 7 | 9.8 | 86 | 83.2 | 1.178 | 3 | .758 |
| | anaemia | | | | | | | | | | | | | | | | | | | |
| 18 | Blood test for | 21 | 32.7 | 127 | 115.3 | 31 | 25.2 | 83 | 88.8 | 23 | 11.5 | 29 | 40.5 | 15 | 20.6 | 78 | 72.4 | 23.807 | 3 | .000 |
| | malaria parasite | | | | | | | | | | | | | | | | | | | |
| 19 | BP measurement | 2 | 3.6 | 146 | 144.4 | 3 | 2.8 | 111 | 111.2 | 2 | 1.3 | 50 | 50.7 | 3 | 2.3 | 90 | 90.7 | 1.417 | 3 | .701 |
| | Cluster Value | | | | | | | | | | | | | | | | | 38.862 | 12 | .000 |
| - | Immunization | 2 | 0.0 | 1.45 | 100.0 | 10 | | 104 | 106.4 | 10 | 2.4 | 10 | 40.6 | | <i>c</i> a | 0.1 | 06.0 | 21.620 | 2 | 000 |
| 20 | TTT dose | 5 | 9.8 | 145 | 138.2 | 10 | 7.6 | 104 | 106.4 | 12 | 3.4 | 40 | 48.6 | 2 | 6.2 | 91 | 86.8 | 31.630 | 3 | .000 |
| 21 | 112 dose | 31 | 44.0 | 0 | 104.0 | 39 | 33.9 | 15 | 80.1 0.8 | 15 | 15.5 | 51 | 30.5 | 30 07 | 27.0 | 51 | 05.4 | 10.1/1 | 3 | .017 |
| 22 | TT4 doce | 140 | 133.3 | 0 | 12./ | 99 112 | 104.2 | 2 | 9.6 | 40 | 47.5 51.6 | 0 | 4.5 | 07 | 02.2 | 0 | 8.0 7 | 0.032 | 2 | .109 |
| 23 | TT5 dose | 14/ | 136.6 | 2 | 1.1 8.4 | 105 | 107.6 | 2 0 | .0 6.4 | 32 41 | J1.0 40.1 | 11 | .+ 20 | 93 02 | 92.5 877 | 1 | ./ 53 | 23 300 | 3 | |
| 24 | Cluster Value | 140 | 150.0 | 4 | 0.4 | 105 | 107.0 | ' | 0.4 | 41 | 47.1 | 11 | 2.) | 12 | 07.7 | 1 | 5.5 | 20 378 | 15 | 158 |
| | Overall Value | | | | | | | | | | | | | | | | | 19 446 | 12 | 078 |
| | Oreran value | | | | | | | | | | | | | | | | | 17.440 | 14 | .070 |

Cal²19.446,Pvalue=.078,df=12,P>.05

Table 7 the X^2 calculated value of 19.446 with corresponding P-value of .078 which is greater than .05 level of significance at 12 degree of freedom. The null hypothesis of no significant difference in the utilization of ANC services among pregnant women based on parity is therefore accepted. This means that utilization of ANC services does not differ significantly based on parity.

Discussion

Data in Table 1 showed that most (73.8) pregnant women utilized the components of ANC services. The table reveals the proportion of the respondents that utilized specific components of ANC services as follows: health education (96.7%), screening (90.5%), routine drugs (80.8%), physical examination (65.0%) and immunization (35.7%). The increase in the utilization of ANC services was expected because of the free ANC services initiated by the State and Federal Government. It is expected that pregnant women utilize ANC services to prevent pregnancy complications, improve maternal health and improve neonatal health. This result is in line with Kulkarni and Nimbalkar (2012) findings who reported that the utilization of antenatal care by pregnant women was 78.8 percent. Conversely, Awusi, Anyanwu, and Okeleke (2012) reported that, of the 200 pregnant women studied, 113 (57%) utilized ante-natal care services during pregnancy while 87 (43%) did not. Furthermore, Adewoye, Musa, Atoyebi and Babatunde (2013) reported that there was high antenatal care utilization, (76.8%) among pregnant women. Similarly, Chukwuma, Uche, Kelechi, Kelvin, Irene, Henry and Chima (2015) indicated that a good proportion of the mothers (90.1%) utilized antenatal services, at least, once during their most recent pregnancies, while 80.3% had skilled attendants at delivery.

Data in Table 2 showed that, pregnant women aged 46 years and above (33.3%) recorded the highest utilization of ANC services, followed by pregnant women aged 33-45 years (28.9%), below 19 years (28.6) and 19-25 years (24.6%). This means that pregnant women aged 46 years and above utilized ANC services more than others. This finding is expected because pregnant women at these

age bracket (46 years and above) had various experiences/ complications which may prompt them to utilize ANC services; more so, pregnant women at these age group are at high risk of pregnancy complications. Even though pregnant women aged 19 years and below are also at high risk of pregnancy complications but, they may not utilize ANC services due to fear of stigmatization and feeling of shame. However, Overbosch et al (2002) stated that, pregnancy is a natural process and pregnant women with some experience due to their age might consider utilization of ANC services less necessary. In contrast, the author further reported that women aged above 45 years are also possibly more confident and influential in decision making which may prompt them to utilize ANC services than women below 20 years. In addition, Burgard (2004) reported that early age pregnant women are more likely to suffer from severe complications during pregnancy, which may result in higher morbidity and mortality for both themselves and their fetuses; this may trigger them to utilize ANC services. Furthermore, older women may belong to older traditional cohorts and thus be less likely to use modern facilities than young women (Navaneetham & Dharmalingam, 2002).

Result in Table 5 showed that there was significant difference in the utilization of ANC services among pregnant women based on age. This finding is expected because Burgard (2004) view mother's age to play an important role in utilization of ANC services, though the direction of the effect is often contradictory.

Based on location of the pregnant women in the study as indicated in Table 3, pregnant women in rural area (26.9%) utilized ANC services than their counterparts in the urban area (23.4%). This is perplexing and unexpected because pregnant women who live in urban area are supposed to be more civilized and advanced; these should prompt them to utilize ANC services more. This finding is not congener with that of Abor and Abekah (2009) that urban dwellers may utilize ANC services more than rural dwellers due to distance from health facility. Similarly, Overbosch et al. (2002) reported that currently, utilization of ANC services prompts a number of rural women to travel more than 5km to the health facilities. This shows that urban dwellers may utilize ANC services more than their rural counterpart. In the same way, Chakraborty (2003) stated that proximity to a health facility has been found to affect the utilization of ANC services especially in rural areas as these facilities are usually located at long distances. Moreso, Celik and Hotchkiss, (2012) concluded that differential access to health care facilities between the rural and urban centres reduced utilization of ANC services for the rural dwellers.

Result Table 6 showed that there was significant difference in the utilization of ANC services among pregnant women based on location. This finding implies that location influences utilization of ANC services. This finding is expected and have collaborates with that of Acharya and Cleland, (2000) who reported a negative effect of distance and/ or travel time to ANC utilization. In contrast, Overbosch et al., (2002) reported a positive association with quality of ANC services. Place of residence (rural/urban) and geographical location (region) may also affect the utilization of ANC services; urban dwellers may be relatively closer to health care facilities than rural dwellers in most developing countries (Abor & Abekah, 2009).

Based on parity of the pregnant women as indicated in Table 4, pregnant women who had 3-4 children (28.1%) recorded the highest utilization of ANC services followed by pregnant women who had 5 children and above (27.0%) and those with first pregnancy (24.7) while respondents with 1-2 children (24.5%) recorded the lowest. Little or no surprise came from this result in view of available literature. Magadi (2005) revealed that, women with 2-4 children ever born were twice as likely to utilize ANC services as women with only one child. In contrast, due to uncertainty and the perception of risk associated with first pregnancies, women are more likely to utilize ANC services for first-order births than subsequent ones. Moreover, having many children may cause resource constraint, which has been found to be negatively associated with ANC services utilization (Chakraborty, 2003). Similarly, the greater confidence and experience of the older and higher parity women, together with greater responsibilities within the household and for child care, have been suggested as explanatory factors for their tendency to use services less frequently (Kwast & Liff, 2008). Furthermore, if a woman ever had a stillbirth in a previous pregnancy, the utilization of ANC services would be higher because of known risk involve in childbirth (Furuta & Salway, 2006).

Table 7 showed that there was no significant difference in the utilization of ANC services among pregnant women based on parity. This implies that utilization of ANC services is the same according to different parity status of pregnant women. Literature has it that parity has a strong

relationship that has been shown to exist between birth order and utilization of ANC services (Kamal, 2009). However, Raghupathy (2006) reported that a higher number of previous pregnancies are associated with less utilization of ANC services. This means that number of living children of the pregnant women may affect her utilization of ANC services.

Conclusion

Based on the result of the findings, the following conclusions were drawn:

- 1. Overall per cent (73.8%) proportion of pregnant women utilizing of ANC services. Pregnant women aged 46 years and above recorded the highest (33.3%) while those aged 19-25 years recorded the lowest (24.6%) utilization of ANC service.
- 2. Slightly lower of proportion of pregnant women in rural area (26.9%) recorded the highest while pregnant women in the urban area (23.4%) reported lowest utilization of ANC services.
- 3. Proportion of ANC services utilization based on parity by pregnant women with 3-4 children (28.1%) recorded the highest while pregnant women with 1-2 children (24.5%) reported lowest.
- 4. There was significant difference in the utilization of ANC services among pregnant women based on age and location among pregnant women, while was no significant difference in the utilization of ANC services among pregnant women based on parity.

Recommendations

Based on the findings of this study, the following recommendations were made:

- 1. Health education and campaign on adequate utilization of antenatal care services (especially physical examination & immunization) should be conducted by health educators and other health care professionals regularly at health centres, schools, churches, social media, among others.
- 2. Also, contentiousness of staff to patients should be advocated by ANC clinics so that more pregnant women (particularly young mothers) will be encouraged to utilize ANC services.
- 3. Government should provide more health care centres in various areas in order to avoid distance as being an excuse of location of health care centre, or if possible, vehicles be provided to various local government to bring about efficient transportation to the health care centres.
- 4. Campaigns against social norms that is harmful to women's health such as early marriage and high parity; and stigmatization of unwed teenage mothers.

References

- Dairo, M. D., & Owoyokun K. E. (2010). Factors affecting the utilization of antenatal care services in Ibadan, Nigeria. *Journal of Post graduate Medicine*. 12,1-6.
- Emelumadu, O.F., Ukegbu, A. U., Ezeama, N.N., Kanu, O.O. Ifeadike, C.O. & Onyeonoro, U. (2015). Socio- Demographic Determinants of Maternal Health- Care Service Utilization Among Rural Women in Anambra State, South East Nigeria, *Reproductive Sciences* DOI: 10.4236/arsci.2015.33005.
- Federal Ministry of Health. (2005). National Reproductive Health Policy and Strategy. Abuja, Nigeria: Federal Ministry of Health.
- Federal ministry of health. (2012). Road map for accelerating the attainments of MDGs related to maternal and newborn health in Nigeria.
- Fosu, G. B. (2011). "Childhood morbidity and health services utilization: cross national comparisons of user-related factors from DHS data", *Social Science Medicine*, 38, (9) 1209-1220.
- Gemson, G.S. & Kyamru, J.I. (2013). *Theory and practice of research methods for the health and social sciences* (Rev ed). Jalingo: Livingstone Educational Publishing Enterprise (Nig).
- Ikeoluwapo, O. A, Damilola, C. Osakinle, (2013). Socio demographic factors determining the adequacy of antenatal care among pregnant women visiting Ekiti State primary health centres. Available from: http://www.reproductive-health-journal.com/content/pdf/1742-4755-6-9.pdf.

- Jibo, A. A. (2005). Utilization of antenatal services at the Provincial Hospital, Mongomo, Guinea Equatoria. *African Journal Reproductive Health*,7, 49-54.
- Magadi, M. A., Agwanda, A. O., & Obare, F. O. (2007). A comparative analysis of the use of maternal health services between teenagers and older mothers in sub-Saharan Africa: Evidence from demographic and Health Surveys (DHS). Social Science Medicine 64:1311– 1323.
- Onah, H. E., Ikeako, L. C., & Iloabachie, G. C. (2006). 'Factors associated with the use of maternity services in Enugu south east Nigeria'. *Social Sciences Medicine*, 2006 Oct; 63(7): 1870-78 [Online] Retrieved from: http://www.sciencedirect.com.ezproxy.liv.ac.uk/science.
- Toan, T. K. (2012). Antenatal And Delivery Care Utilization in Urban and Rural Contexts in Vietnam: A study in two health and demographic surveillance sites, thesis at the Nordic School of Public Health NHV Gothenburg, Sweden.
- UNDP (2016). Socio-cultural influences on the reproductive health of migrant women: A review of literature in Vitenam. Hanoi: Vietnam Country Office.
- Villar, J. (2012) WHO antenatal care randomised trial for the evaluation of a new model of routine antenatal care. The Lancet 357(9268), 1551–1564.
- WHO (2005). The World Health Report 2005. WHO, Geneva. World Health Organization .The World Health Report (2005), Geneva.
- WHO (2009). Improved accesses to maternal health services. WHO 98.7, Geneva.
- WHO (2010). The WHO Antenatal Care: Randomized Controlled Trial- Manual for implementation of the new model. In: *WHO programme to map best reproductive health practices*, Geneva.
- WHO (2012). Save the Children: Women on the Front Lines of Health Care: State of the World's Mothers, Connecticut, USA.
- WHO, UNICEF & UNFPA (2007). Advocacy Brief: In Family Planning/Child Birth Spacing for Health and national Development Action Points for Policymaker. Produced by the Federal Ministry of Health with support from ENHANCE project/USAID.